FEMY

0.76% -0.0032

Dopo l'orario di chiusura: .42 0.003 +0.72%

Femasys Inc (FEMY)

Panoramica Notizia Cronologia dei prezzi Financials Perché FEMY Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Femasys Inc Stock (FEMY) Company Profile

Healthcare (1116)

770-500-3910

3950 JOHNS CREEK COURT, SUWANEE

Prossima data di guadagno

Ultimi documenti SEC

FEMY's Discussions on Twitter

Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FEMY Femasys Inc	0.417	25.00M	2.06M	-19.80M	-20.12M	-0.7203
ISRG Intuitive Surgical Inc	464.45	163.73B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	156.34	44.73B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	75.51	36.73B	10.40B	980.00M	1.61B	1.9749
MDLN Medline Inc	44.00	36.12B	28.43B	1.16B	1.26B	1.4457
RMD Resmed Inc	222.85	32.70B	5.40B	1.49B	1.78B	10.12

Femasys Inc Stock (FEMY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-20	Iniziato	Laidlaw	Buy

Femasys Inc Borsa (FEMY) Ultime notizie

Femasys Inc Azioni (FEMY) Dati Finanziari

Femasys Inc (FEMY)

Femasys Inc Stock (FEMY) Company Profile

Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD

Femasys Inc Stock (FEMY) Upgrades & Downgrades

Femasys Inc Borsa (FEMY) Ultime notizie

FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan

Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan

Femasys Names John Canning as New Chief Operating Officer - tipranks.com

Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com

Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - Bitget

Femasys names John Canning as chief operating officer - investing.com

Femasys names John Canning as Chief Operating Officer - tradingview.com

Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan

Medtech veteran joins Femasys to scale fertility, birth control products - Stock Titan

Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - National Today

Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan

Femasys 2025 sales jump on FemBloc demand - TradingView

Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan

Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - tradingview.com

Permanent birth control developer starts U.S. trial, cash lasts into Q3 2026 - Stock Titan

FEMY Should I Buy - intellectia.ai

Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan

Femasys (NASDAQ: FEMY) director receives 102,366 Series D-1 stock warrants - Stock Titan

Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan

Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan

Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart

Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com South Africa

Femasys amends warrants and notes, appoints new director to board - Investing.com

Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan

Femasys Amends Financing Terms and Issues New Warrants - TipRanks

Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - marketscreener.com

Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView

Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - tradingview.com

Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan

Femasys Inc. announced that it has received $12 million in funding - marketscreener.com

Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa

PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan

Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan

PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan

Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com

Femasys appoints anesthesiologist to board of directors - Investing.com

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget

Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative

Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com

Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView

Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria

Jeremy Alexander Sipos Net Worth (2026) - GuruFocus

Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN

Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN

Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com Australia

Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan

Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World

PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits

Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital - Defense World

Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia

Femasys Inc Azioni (FEMY) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a FEMY